InvestWiser

Herantis Pharma Oyj

HRTISNasdaq HelsinkiHealthcareMarket value 37 m EUR
1.40EUR 0.0%
last day · Price as of 18 November 2026

The answer first

Does Herantis Pharma beat the market?

No, Herantis Pharma has not beaten the market over the last year.

Herantis Pharma−31.4%Helsinki (OMXHGI)+17.3%
  • The ranking · Quality, value and trend combined

    Better than 0% of Nordic stocks

    • Quality1
    • Value5
    • Trend16

    No. 194 of 195 in healthcare

Max for seven days

Follow Herantis Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Herantis Pharma

From today, at a price of 1.40 EUR. Write why you follow Herantis Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Herantis Pharma

Your first answer is free, no account needed.

Do you own Herantis Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Herantis Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Herantis Pharma−31.4%Helsinki (OMXHGI)+17.3%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Herantis Pharma has fallen 31.4% over the past year, including dividends.
  • Overall, Herantis Pharma ranks better than 0% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 73.6%. The price is 86.6% below its peak now.

What do analysts think of Herantis Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

0

Quality, value and trend together. Better than 0% of Nordic stocks.

No. 194 of 195 in healthcare

Quality1
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 196 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity−4.33
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−392.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value5
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 163 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50

  • P/BPrice divided by equitynegative earnings
  • P/SPrice divided by sales288.3
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend16
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 138 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−11.8%
  • 6 months−23.7%
  • 9 months−35.5%
  • 12 months−31.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+10.6%
3 years, per year
−5.5%
5 years, per year
−13.4%
10 years, per year
+0.5%
Largest fall, 3 years
−73.6%
From a peak to the bottom
From the peak now
−86.6%
How far the price is from the peak
Volatility, 1 year
56.1%
How much the price swings over a year
Beta, 1 year
0.93
How much the price moves when the market moves

Return with dividends reinvested.

About Herantis Pharma

Herantis Pharma Oyj is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 14 employees.

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.

See the full analysis of Herantis Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Helsinki

Explore the stock market